skip to main content



Previous studies of semaglutide have shown that using semaglutide reduced the risk of cardiovascular events in some people with type 2 diabetes. Semaglutide is already approved in some countries at a lower dose, to treat type 2 diabetes. The SELECT study will examine the effect of semaglutide in people with established cardiovascular disease and obesity or overweight. 

Initially, you will go through a screening process at Moorgreen Hospital to ensure that you meet the criteria for being included in the SELECT study. If you do, the study doctor will explain exactly what is expected of a study participant so you can make an informed decision. Participation in the SELECT study will include:

  • A once-weekly injection of the study medicine, prescribed by the study doctor
  • Attending regular study visits for study-related health checks
  • Regular contact with the study nurse or doctor throughout the study

To take part you must meet the following criteria:

  • Male or female, age ≥ 45 years at the time of signing informed consent
  • Body mass index (BMI) ≥ 27 kg/m2 (overweight)
  • Have established cardiovascular disease – previous heart attack / stroke / PAD (peripheral arterial disease)



You cannot take part if you had a TIA (Transient Ischaemic Attack) as opposed to a stroke.

If you would like to take part or want more information please contact the study lead:

Study Contact: Juliette Meek - Senior Research Nurse


Tel: 02380 475258

Page Comments